Intra-cellular Therapies, Inc. Share Price: ITCI (Intra-cellular Therapies, Inc.) Stock Price Today & Updates | INDmoney

Question 1

What is Intra-cellular Therapies, Inc. share price today?

Accepted Answer

Intra-cellular Therapies, Inc. (ITCI) share price today is {{live_price}}.

Question 2

Can Indians buy Intra-cellular Therapies, Inc. shares?

Accepted Answer

Yes, Indians can invest in the Intra-cellular Therapies, Inc. (ITCI) from India.

With INDmoney, you can buy Intra-cellular Therapies, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Intra-cellular Therapies, Inc. at zero transaction cost.

Question 3

How can I buy Intra-cellular Therapies, Inc. shares from India?

Accepted Answer

It is very easy to buy Intra-cellular Therapies, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Intra-cellular Therapies, Inc. be purchased?

Accepted Answer

Yes, you can buy fractional shares of Intra-cellular Therapies, Inc. with INDmoney app.

Question 5

What are the documents required to start investing in Intra-cellular Therapies, Inc. stocks?

Accepted Answer

To start investing in Intra-cellular Therapies, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Intra-cellular Therapies, Inc.

Accepted Answer

Today’s highest price of Intra-cellular Therapies, Inc. (ITCI) is {{1_rba_end}}.

Today’s lowest price of Intra-cellular Therapies, Inc. (ITCI) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Intra-cellular Therapies, Inc.

Accepted Answer

Today's market capitalisation of Intra-cellular Therapies, Inc. ITCI is 8.2B

Question 8

What is the 52 Week High and Low Range of Intra-cellular Therapies, Inc.

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Intra-cellular Therapies, Inc. is down from its 52 Week High?

Accepted Answer

Intra-cellular Therapies, Inc. (ITCI) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Intra-cellular Therapies, Inc. is up from its 52 Week low?

Accepted Answer

Intra-cellular Therapies, Inc. (ITCI) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Intra-cellular Therapies, Inc.?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Intra-cellular Therapies, Inc.

Accepted Answer

Dr. Sharon  Mates Ph.D. is the current Chief Executive Officer (CEO) of Intra-cellular Therapies, Inc..

Period	Intra-cellular Therapies, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	10.35%	6.5%	0.0%
6 Months	19.99%	7.1%	0.0%
1 Year	31.77%	9.8%	0.0%
3 Years	131.97%	14.2%	-20.2%

Market Capitalization	8.2B
Book Value	$6.15
Earnings Per Share (EPS)	-1.16
PEG Ratio	0.0
Wall Street Target Price	93.71

Profit Margin	-21.57%
Operating Margin TTM	-14.46%

Return On Assets TTM	-11.23%
Return On Equity TTM	-18.07%

Revenue TTM	513.9M
Revenue Per Share TTM	5.34
Quarterly Revenue Growth YOY	52.0%
Gross Profit TTM	95.2M
EBITDA	-131.4M
Diluted Eps TTM	-1.16
Quarterly Earnings Growth YOY	0.0

Intra-cellular Therapies, Inc. (ITCI)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Technicals Summary

Peers

Increasing Revenue

Increasing Net Profit

Vs NBIX

Institutional Holdings

Corporate Announcements

Intra-cellular Therapies, Inc. Earnings

Company Information

Discover More

FAQs

EPS Estimate Current Year	-0.55
EPS Estimate Next Year	1.08
EPS Estimate Current Quarter	-0.32
EPS Estimate Next Quarter	-0.2

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Intra-cellular Therapies, Inc.	13.72%	19.99%	31.77%	131.97%	865.83%
Neurocrine Biosciences Inc.	7.56%	2.78%	45.55%	52.55%	67.01%
Haleon Plc Spon Ads	7.53%	11.87%	3.28%	23.35%	23.35%
Zoetis Inc.	5.77%	-5.62%	-5.85%	-9.99%	57.03%
Viatris Inc.	12.75%	-1.42%	12.21%	-15.03%	-28.03%
Catalent, Inc.	4.08%	11.91%	19.53%	-48.27%	2.08%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.55	-0.18	-0.11	NA	6.15
Neurocrine Biosciences Inc.	39.75	39.75	0.44	3.99	0.18	0.1	NA	23.72
Haleon Plc Spon Ads	29.9	29.9	1.69	0.39	0.07	0.04	0.02	1.8
Zoetis Inc.	34.62	34.62	2.58	5.77	0.5	0.14	0.01	11.07
Viatris Inc.	224.4	NA	0.06	2.73	0.0	0.03	0.04	16.81
Catalent, Inc.	211.02	NA	2.06	0.2	-0.28	-0.01	NA	19.96

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Intra-cellular Therapies, Inc.	Buy	$8.2B	865.83%	NA	-21.57%
Neurocrine Biosciences Inc.	Buy	$14.7B	67.01%	39.75	18.65%
Haleon Plc Spon Ads	Buy	$41.0B	23.35%	29.9	9.64%
Zoetis Inc.	Buy	$82.0B	57.03%	34.62	27.38%
Viatris Inc.	Hold	$14.2B	-28.03%	224.4	-0.37%
Catalent, Inc.	Hold	$10.6B	2.08%	211.02	-28.44%

Organization	Intra-cellular Therapies, Inc.
Employees	610
CEO	Dr. Sharon Mates Ph.D.
Industry	Health Technology